Oncothyreon Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncothyreon

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: LJM who wrote (2005)	2/26/2007 11:59:40 AM
From: Jibacoa	Read Replies (1) of 2344

And today announced that the first patient has been enrolled in the global PIII, (START)to assess the efficacy and safety of Stimuvax, its BLP25 liposome vaccine for patients with unresectable stage III NSCL. The trial is being conducted by Merck KGaA & its U.S. affiliate EMD Pharmaceuticals.(BIOM is entitled to receive a milestone payment from MRK upon enrollment of the first patient in this trial, albeit the amount of $$$ hasn't been disclosed.) BIOM's CEO, Dr. Kirkman also mentioned that in 2007 BIOM expects to make progress in advancing its clinical pipeline. The PII of PX-12 in patients with advanced pancreatic cancer is ongoing and its expects to bring PX-478 into clinical development at mid-year. The stock opened with a small UG, but the advance was halted on an intraday double top at the 1.23 level.<g> bigcharts.marketwatch.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next